A Placebo-Controlled Double-blind Parallel-group 18 Month Study To Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease

Brief description of study

This is a research study to evaluate the safety and effectiveness of the study drug BAN2401.BAN2401 is given by an intravenous infusion, which is an injection into a vein. The infusion will drip through the infusion tubing for about 60 minutes. During the study drug period, you will receive study drug or placebo injections, every 2 weeks for up to 18 months during the main study period.

Clinical Study Identifier: s19-00304
ClinicalTrials.gov Identifier: NCT03887455

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.